Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01893151 |
Recruitment Status : Unknown
Verified July 2013 by Jiangsu Simcere Pharmaceutical Co., Ltd..
Recruitment status was: Recruiting
First Posted : July 8, 2013
Last Update Posted : October 23, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rheumatoid Arthritis | Drug: Iguratimod Drug: Iguratimod placebo | Phase 4 |
Magnetic resonance imaging (MRI) is a powerful imaging modality that is now widely used in both scientific research and clinical settings to visualise joints of patients with RA. MRI is able to image structural damage and soft tissue changes, ie, synovitis, bone oedema, damage to cartilage and bone, as well as tendon pathology. MRI is more responsive to change in joint damage and can be used to monitor disease progression.
In this studly,MRI of the dominant wrist was performed at baseline ,24 weeks and at 52 weeks, using a 1.5T or 3.0T MRI with a dedicated high-resolution wrist phased array coil.The same scanner and wrist coil were used for three examinations. The hand was placed in the wrist coil at the patient's side with the coil anchored to the base tray to reduce motion artefacts. The MRI sequences in this study included the OMERACT recommended MRI core set of sequences.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI) |
Study Start Date : | July 2012 |
Estimated Primary Completion Date : | December 2015 |
Estimated Study Completion Date : | December 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: Iguratimod
Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
|
Drug: Iguratimod
Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
Other Name: Iremod |
Placebo Comparator: Iguratimod placebo
Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week;Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week
|
Drug: Iguratimod placebo
Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week; Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week. |
- Change from baseline in RA magnetic resonance imaging scoring system (RAMRIS) [ Time Frame: week 52 ]
- Change from baseline in modified Total Sharp Score (mTSS) [ Time Frame: week 52 ]
- Percentage of patients with ACR 20 response [ Time Frame: week 52 ]
- Change in Disease Activity as measured by the DAS28 [ Time Frame: week 52 ]
- Change from baseline in RAMRIS [ Time Frame: week 24 ]
- Change from baseline in mTSS [ Time Frame: week 24 ]
- Percentage of patients with ACR 20 response [ Time Frame: week 10, week 24, week 40 ]
- Change from baseline in Disease Activity Score 28 (DAS28) [ Time Frame: : week 10, week 24, week 40 ]
- Percentage of patients with ACR 50 response [ Time Frame: week 10, week 24, week 40, week 52 ]
- Percentage of patients with ACR 70 response [ Time Frame: week 10, week 24, week 40, week 52 ]
- Percentage of patients with Simplified Disease Activity Index (SDAI) ≤ 3.3 [ Time Frame: week 10, week 24, week 40, week 52 ]
- Change from baseline in Simplified Disease Activity Index (SDAI) [ Time Frame: week 10, week 24, week 40, week 52 ]
- Change from baseline in Health Assessment Questionnaire (HAQ) [ Time Frame: week 10, week 24, week 40, week 52 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects with a diagnosis of RA according to the diagnostic criteria of the American College of Rheumatology (ACR) (revised in 1987)
- Rheumatoid Arthritis for 3 months to 2 years from the time of the initial diagnosis
- Functional Class II-III
- Subjects have active RA at the time of screening
- Must have a negative Pregnancy test and use adequate method of contraception throughout the trial
- Must have at least 4 tender joints and 4 swollen joints(involved in DAS28) and among these,at least one swollen Metacarpophalangeal joint is essential
- Has a C-reactive protein ≥ 10 mg/L OR Erythrocyte Sedimentation Rate (ESR) ≥ 28 mm/hr
- Written informed consent
Exclusion Criteria:
- Preceding treatment with DMARDs, immunosuppressants (cyclophosphamide, cyclosporine, azathioprine, etc.), biological agents or tripterygium within 12 weeks prior to study entry
- Chest x-ray abnormalities, such as tuberculosis, interstitial pulmonary fibrosis, etc
- ALT >1.5×ULN, AST >1.5×ULN, Cr >135umol/L or Cr >1.5mg
- WBC<4×109/L,HGB<85g/L,PLT<100×109/L
- Subjects with serious cardiovascular, renal, hematologic,endocrine diseases or malignant
- Subjects with immunodeficiency, uncontrolled infection and active gastrointestinal disease
- Pregnant, intend to become pregnant, or are breastfeeding
- Subjects with other rheumatological diseases such as SLE, mixed connective tissue disease, scleroderma, polymyositis, etc
- Subjects with inflammatory arthritis, such as gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease
- Subjects with intra-articular corticosteroid injections within 6 weeks prior to study entry
- Allergic to any of the study drugs
- History of alcoholism
- Subjects with mental illness
- Subjects receiving live vaccines recently
- Subjects participating in other clinical study within 3 months prior to study entry

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01893151
China, Guangdong | |
Third Affiliated Hospital Of Sun Yat-sen University | Recruiting |
Guangzhou, Guangdong, China, 510630 | |
Contact: Gu gujieruo@163.com |
Principal Investigator: | Jieruo Gu, Doctor | Third Affiliated Hospital, Sun Yat-Sen University |
Responsible Party: | Jiangsu Simcere Pharmaceutical Co., Ltd. |
ClinicalTrials.gov Identifier: | NCT01893151 |
Other Study ID Numbers: |
SMM-3 |
First Posted: | July 8, 2013 Key Record Dates |
Last Update Posted: | October 23, 2014 |
Last Verified: | July 2013 |
Iguratimod MRI Rheumatoid Arthritis |
Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases |
Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases |